Maravai LifeSciences' (MRVI) TriLink BioTechnologies said Monday it partnered with Avantor (AVTR) to expand the availability of its innovative nucleic acid products to customers across Europe, the Middle East, and Africa.
The company said the distribution partnership is expected to streamline the ordering process and shorten lead times for European customers.
Under the agreement, TriLink's key products, including CleanCap cap analogs, catalog mRNAs, over 150 modified and unmodified nucleotides, and high-performance IVT enzymes like CleanScribe RNA Polymerase, are more widely available in the region.
It added that TriLink's products will soon be available on Avantor's eCommerce platform, MarketSource.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。